Research
Hormonal
Tirzepatide is the first dual receptor agonist incorporated into therapeutic recommendations for type 2 diabetes.
Tirzepatide should be considered as a treatment option for type 2 diabetes.
StrongSupportsmedium confidence
It describes the pharmacology of the first dual receptor agonist, tirzepatide, already incorporated in therapeutic recommendations.
Why this rating
The claim is based on clinical trials mentioned in the abstract.
Source
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Gábor Winkler et al. · Orvosi Hetilap · 2023
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →